Drug Trial Radar · NCT02649790
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications
Last checked: Nov 20, 2026Latest source record: Mar 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
277
Planned (sponsor's estimate)
Start
Jan 2016
Primary completion
Aug 31, 2024
Study completion Dec 23, 2024
Sponsor
- Lead sponsor
- Karyopharm Therapeutics IncIndustry
- Sponsor type
- Industry
- First posted
- Jan 7, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first-in-human, multi-center, open-label clinical study with separate dose escalation (Phase 1) and expansion (Phase 2) stages to assess preliminary safety, tolerability, and efficacy of the second generation oral XPO1 inhibitor KPT-8602 in participants with relapsed/refractory multiple myeloma (MM), metastatic colorectal cancer (mCRC), metastatic castration resistant prostate cancer (mCRPC), higher risk myelodysplastic syndrome (HRMDS), acute myeloid leukemia (AML) and newly diagnosed intermediate/high-risk MDS. Dose escalation and dose expansion may be included for all parts of the study as determined by ongoing study results.
Conditions
- Relapsed/Refractory Multiple Myeloma (RRMM)
- Metastatic Colorectal Cancer (mCRC)
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Higher-Risk Myelodysplastic Syndrome (HR-MDS)
- Acute Myeloid Leukemia (AML)
- Newly Diagnosed Intermediate/High-Risk MDS
Interventions
KPT-8602Drug
Participants will receive KPT-8602 oral tablets.
ASTX727Drug
ASTX727 is a combination drug of 35 mg decitabine and 100 mg cedazuridine.
DexamethasoneDrug
Participants will receive dexamethasone oral tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A1, A2, B, C, D, E, F: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)Time frame: Approximately 4 weeks
- Part A1, A2, B, C, D, E, F: Overall Response Rate (ORR)Time frame: Approximately 8 years
- Part A1, A2, B, C, D, E, F: Duration of Response (DOR)Time frame: Approximately 8 years
- Part A1, A2, B, C, D, E, F: Progression-free Survival (PFS)Time frame: Approximately 8 years
- Part A1, A2, B, C, D, E, F: Overall Survival (OS)Time frame: Approximately 8 years
- Part A1, A2, B, C, D, E, F: Clinical Benefit Rate (CBR)Time frame: Approximately 8 years
- Part A1, A2, B, C, D, E, F: Duration of Clinical Benefit Rate (CBR)Time frame: Approximately 8 years
- Part A1, A2, B, C, D, E, F: Disease Control Rate (DCR)Time frame: Approximately 8 years
- Part A1, A2, B, C, D, E, F: Duration of DCRTime frame: Approximately 8 years
- Part F Phase 2: ORRTime frame: Approximately 8 years
- Part G: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)Time frame: Approximately 8 years
- Part H: 2- Year Progression-free Survival (PFS)Time frame: Approximately Up to 2 years
Locations
46 sites in 5 countries. Site status is shown where the registry gives one.
David Geffen School of Medicine at UCLA
Los Angeles, California
Oncology Institute of Hope and Innovation
Pasadena, California
Rocky Mountain Regional VA Medical Center
Aurora, Colorado
Sarah Cannon Cancer Center - (Colorado Blood Cancer Institute)
Denver, Colorado
(USO) Rocky Mountain Cancer Centers
Littleton, Colorado
Moffitt Cancer Center
Tampa, Florida
Cancer and Hematology Centers of Western Michigan
Grand Rapids, Michigan
Sarah Cannon Cancer Center (HCA Midwest KC)
Kansas City, Missouri
Callahan Cancer Center
North Platte, Nebraska
John Theurer Cancer Center at Hackensack UMC
Hackensack, New Jersey
University of New Mexico
Albuquerque, New Mexico
Weill Cornell Medical College
New York, New York
(USO) Oncology Hematology Care
Cincinnati, Ohio
Ohio State University, The James Cancer Hospital and Solove Research Institute
Columbus, Ohio
University of Pennsylvania Abramson Cancer Center Clinical Research Unit
Philadelphia, Pennsylvania
Baptist Cancer Center
Memphis, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee
(USO) Texas Oncology Austin - Midtown
Austin, Texas
(USO) Texas Oncology (Dallas)
Dallas, Texas
MD Anderson Cancer Center
Houston, Texas
(USO) Texas Oncology (Tyler)
Tyler, Texas
Huntsman Cancer Institute
Salt Lake City, Utah
University of Virginia
Charlottesville, Virginia
(USO) Virginia Cancer Specialists
Fairfax, Virginia
University of Washington
Seattle, Washington
(USO) Compass oncology
Vancouver, Washington
McMaster - Juravinski Cancer Centre
Hamilton, Ontario, Canada
Princess Margaret Cancer Center
Toronto, Ontario, Canada
Princess Margaret Cancer Research
Toronto, Ontario, Canada
MUHC GLEN Site Cedars - Cancer Centre
Montreal, Quebec, Canada
China, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China
CHU Nantes
Nantes, France
Hôpital Cochin APHP
Paris, France
Hôpital Necker
Paris, France
Hôpital St Louis
Paris, France
CHU de Bordeaux
Pessac, France
CHU de Tours
Tours, France
CHRU de Nancy
Vandœuvre-lès-Nancy, France
Clínica Universidad de Navarra
Barcelona, Spain
Showing 40 of 46 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.